X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RC18 (telitacicept) targets two cell-signaling molecules critical for B-lymphocyte development: BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases.
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: RC18
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
RC88 is a mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), which is under phase 2 clinical development for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Lead Product(s): RC88
Therapeutic Area: Oncology Product Name: RC88
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2024
Details:
The collaboration will focus on conducting clinical trials exploring combination therapies of the novel antibody-drug conjugates, RC88 (targeting MSLN) and RC108 (targeting c-MET), along with the PD-1 inhibitor sintilimab injection (TYVYT®).
Lead Product(s): RC88,Sintilimab
Therapeutic Area: Oncology Product Name: RC88
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 09, 2023
Details:
Under the agreement, Innovent will provide supplies of TYVYT® (sintilimab injection) and RemeGen will conduct Phase 1/2a studies to evaluate the anti-tumor activity of the combination therapy of TYVYT® with RC88 or RC108 in Chinese patients with advanced solid tumors.
Lead Product(s): RC88,Sintilimab
Therapeutic Area: Oncology Product Name: RC88
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 25, 2023
Details:
RC118 is RemeGen's latest advanced antibody-drug conjugate used to treat patients with solid tumors positive for Claudin 18.2 expressions. ADC product pipeline, with no less than four products, including the latest RC118, entering clinical trials or gaining marketing approval.
Lead Product(s): RC118
Therapeutic Area: Oncology Product Name: RC118
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
RC18 (telitacicept) targets two cell-signaling molecules critical for B-lymphocyte development: BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases.
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: RC18
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
Preliminary results from the full analysis set (FAS) showed that at week 52, patients who received RC-18 (telitacicept) had a significantly higher rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) response than those who received placebo.
Lead Product(s): Telitacicept,Interleukin 2
Therapeutic Area: Immunology Product Name: RC-18
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Seagen Licenses Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate (ADC) from RemeGen. Disitamab vedotin is a novel ADC that selectively delivers the anti-cancer agent monomethyl auristatin E (MMAE) into HER2-expressing tumor cells.
Lead Product(s): Disitamab Vedotin
Therapeutic Area: Oncology Product Name: RC48
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: $2,600.0 million Upfront Cash: $200.0 million
Deal Type: Collaboration August 09, 2021
Details:
The approval of Disitamab vedotin has broken the situation that there is no original domestic new drug in the field of ADC drugs, and filled the gap in the global post-line treatment of patients with HER2 over-expression of gastric cancer.
Lead Product(s): Disitamab Vedotin
Therapeutic Area: Oncology Product Name: Aidexi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
U. S FDA has granted Breakthrough Therapy designation for disitamab vedotin, a novel humanized anti-HER2 antibody drug conjugate, for second-line treatment of patients with HER2+ locally advanced/metastatic urothelial cancer, who had received platinum-based chemotherapy.
Lead Product(s): Disitamab vedotin
Therapeutic Area: Oncology Product Name: RC48
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
